Anavex Life Sciences AVXL
NASDAQ AVXL
$1.06 -0.07 (-6.19%)
At close: Nov 11, 2026 · 4:00 PM EST

Anavex Life Sciences (AVXL) Gains from Sales and Divestitures (2012 - 2013)

Updated

Anavex Life Sciences' Gains from Sales and Divestitures came in at $199,655 for FY2014 (year ended Sep 30, 2014).

Analysis

Anavex Life Sciences (AVXL) Gains from Sales and Divestitures (2012 - 2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Anavex Life Sciences 104.75 Mn -375.33 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2013 976,880.00
Dec 31, 2012 -453,517.00
API Access

Anavex Life Sciences Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=AVXL&period=max&api_key=YOUR_API_KEY